Taiwan is mapping out a four-year national pharmaceutical resilience preparedness program that aims to bolster the country’s ...

Atea Pharmaceuticals (NASDAQ:AVIR) outlined progress in its hepatitis C (HCV) late-stage development program and provided an update on its newly expanded hepatitis E virus (HEV) pipeline during its ...

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q4 2025 Earnings Call Transcript March 5, 2026 Lexicon Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.04, expectations were $-0.07.

In today’s Pharmaceutical Executive Daily, the FDA approves Hernexeos under a national priority voucher program, industry ...

Virginia state lawmakers who are tired of waiting are taking matters into their own hands during this year’s legislative ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the most promising penny stocks under $5 to buy. On February 25, ...

On January 27, 2026, the Department of Health and Human Services, Office of Inspector General (“OIG”) published a Special Advisory Bulletin (the “SAB”) addressing key considerations for pharmaceutical ...

This stock looks unstoppable right now.

ORLANDO, FL / ACCESS Newswire / February 27, 2026 / RedChip Companies will air interviews with 60 Degrees Pharmaceuticals, ...

In today’s Pharmaceutical Executive Daily, Alkermes outlines its CEO succession plan following Richard Pops’ retirement announcement, leadership changes continue at Sarepta Therapeutics and Rivus ...

Thanks, everyone, for being here for TD Cowen's 46th Annual Healthcare Conference. Our next session we have here is with Rocket Pharma. And from Rocket, we have Gaurav Shah, the CEO. Thanks so much ...

Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from North American C-BEYOND Trial Expected Mid-2026 and Topline Results from C-FORWARD Trial Outs ...